N/A
N=24
Comparison Between Epinephrine and Clonidine as Adjuvants to Lidocaine in Axillary Brachial Plexus Block.
Brachial Plexus Blockade
Bottom Line
View on ClinicalTrials.gov: NCT03207022 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Sep 2021
Primary outcome: Primary: Onset of Sensory Block — 10; 5 minutes — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- axillary brachial plexus block (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cork University Hospital
- Primary completion
- Jul 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Onset of Sensory Block |
10; 5 | <0.001 sig |
| SECONDARY Onset of Motor Block. |
7.5; 5 | 0.001 sig |
| SECONDARY Duration of Sensory and Motor Block |
165; 218.3 | <0.001 sig |
Summary
Adjuncts to local anaesthetics for the peripheral nerve blocks such as epinephrine, clonidine and opioids have been widely used to enhance quality, duration of anaesthesia and postoperative analgesia. Clonidine, an α2-adrenergic agonist, when combined with local anaesthetics in axillary brachial plexus block has shown to decrease block onset time and prolong the duration of anaesthesia.
We propose to compare the effects of combining both adjuvants to 20 mL of lidocaine 2% on the onset of ultrasound guided axillary brachial plexus block.
Eligibility Criteria
Inclusion Criteria
- ASA 1-2
- Patients age >18 years
- Undergoing elective upper limb (forearm, wrist or hand) surgery.
Exclusion Criteria
- Contraindications to regional anaesthesia
- Hypersensitivity to amide local anaesthetics.
- Chronic pain
- Language barrier
- Neuromuscular disorders or peripheral neuropathy
- H/o postural hypotension or autonomic dysfunction.
- Patients with a known sensitivity for local anaesthetics
- Body mass index > 35
- History of hepatic and renal insufficiency
- Pregnancy
- Cognitive or psychiatric disorder
- Cardiac conduction abnormality.
- Anti arrythmic or adrenergic medications.
Data sourced from ClinicalTrials.gov (NCT03207022). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.